Increasing the activity of BRAF/MEK/ERK inhibitors in CRC and other indications will thus necessitate the use of predictive biomarkers for patient selection, and/or combinations with drugs targeting orthogonal pathways. This evidence concerns the gene BRAF and colorectal carcinoma.